ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F23%3A43925931" target="_blank" >RIV/00064173:_____/23:43925931 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/23:43925931
Result on the web
<a href="https://doi.org/10.1016/j.annonc.2023.08.001" target="_blank" >https://doi.org/10.1016/j.annonc.2023.08.001</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.annonc.2023.08.001" target="_blank" >10.1016/j.annonc.2023.08.001</a>
Alternative languages
Result language
angličtina
Original language name
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
Original language description
The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. Evidence remains limited and/or conflicting in some specific areas where the optimal approach remains controversial. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on controversial topics that cannot be adequately addressed in the current evidence-based ESMO Clinical Practice Guideline. The aim of this consensus-building process was to discuss controversial issues relating to the management of patients with breast cancer during pregnancy. The virtual meeting included a multidisciplinary panel of 24 leading experts from 13 countries and was chaired by S. Loibl and F. Amant. All experts were allocated to one of four different working groups. Each working group covered a specific subject area with two chairs appointed: 1. Breast cancer during pregnancy: incidence, epidemiology, biology and pathology. Diagnostic work up, Staging and Risk assessment, prognosis (Chairs: Vincent Vandecaveye, Fedro Peccatori) 2. Clinical pharmacology of systemic agents during pregnancy. Management of localized disease and (neo) adjuvant therapies. Management of systemic disease (Chairs: Giuseppe Curigliano, Peter Schmid) 3. Obstetric care and fetal/newborn follow-up and outcomes, metastases to fetus. Management of pregnancy during anticancer therapy. Lactation. Psychological support (Chairs: Elyce Cardonick, Mathilde van Gerwen) Planning, preparation and execution of the consensus process was conducted according to the ESMO standard operating procedures.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of Oncology
ISSN
0923-7534
e-ISSN
1569-8041
Volume of the periodical
34
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
18
Pages from-to
849-866
UT code for WoS article
001088552900001
EID of the result in the Scopus database
2-s2.0-85170414993